Welcome to our dedicated page for Palomino Laboratories news (Ticker: PALX), a resource for investors and traders seeking the latest updates and insights on Palomino Laboratories stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Palomino Laboratories's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Palomino Laboratories's position in the market.
Palomino Laboratories (OTCQB: PALX) announced that Co-Founder Dr. Steven P. DenBaars received the 2026 IEEE Nick Holonyak Jr. Medal on April 25, 2026, for contributions to compound semiconductor optoelectronics.
The company also noted its recent OTCQB listing and highlighted Dr. DenBaars’ III-nitride research as foundational to Palomino’s energy-efficient optical interconnect technology for AI data centers.
Palomino Laboratories (OTCQB: PALX) closed a private placement on April 27, 2026, raising $15,095,412 by selling 3,773,853 common shares at $4.00 per share. The company says the proceeds will fund commercialization and scaling of its GaN MicroLED optical interconnect technology for AI data centers and align with CHIPS/NIST priorities.